Mubadala Bio’s Bioventure Healthcare opens high-capacity facility for oncology products

UAE— Mubadala Bio, a leading life sciences company dedicated to improving health outcomes in the UAE and beyond, has opened a new high potency facility at its subsidiary, Bioventure Healthcare.

The launch represents a major step in advancing the UAE’s pharmaceutical manufacturing capabilities and ensuring stable access to essential treatments.

Alongside the opening of the new facility, Mubadala Bio announced the introduction of three essential oncology medicines, some of which are being locally produced for the first time as branded generic products.

This initiative aligns with the company’s goal of strengthening national drug security and supporting the development of a sustainable life sciences ecosystem.

The newly constructed, purpose-built facility is designed to handle high potency drugs, including oncology and hormone products.

It was developed to meet the highest international safety and regulatory standards, ensuring strict quality control and compliance throughout the manufacturing process.

The first products launched from the facility include Lenalidomide, used in the treatment of myeloma, a type of blood cancer; Pomalidomide, locally produced in the UAE for the first time and used to treat multiple myeloma; and Sunitinib, a targeted therapy designed to treat specific types of advanced or progressive cancers.

The local production of these medications provides patients with enhanced access to vital therapies while reducing dependence on imported drugs.

By introducing these critical treatments to the domestic market, Mubadala Bio is contributing to the UAE’s efforts to achieve pharmaceutical self-sufficiency.

The initiative also helps lower healthcare costs, improve treatment continuity, and maintain consistent supply for hospitals and healthcare providers across the country.

Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, highlighted the importance of this achievement.

He stated that launching these locally produced oncology medicines represents a significant addition to Mubadala Bio’s expanding portfolio.

He emphasized that the development supports the growth of a highly advanced life sciences sector in the UAE while offering meaningful benefits to both patients and healthcare professionals.

Dr. Essam Mohamed, CEO of Mubadala Bio, reaffirmed the company’s commitment to strengthening the local life sciences ecosystem.

He noted that by investing in domestic production capabilities and expanding the range of essential oncology medicines, Mubadala Bio is ensuring consistent, reliable access to life-saving therapies for patients.

Deputy CEO Hamad Husein Almarzooqi added that the organization will continue prioritizing the nation’s most critical medical needs.

He explained that the new high potency facility and the production of these three oncology medications reflect Mubadala Bio’s dedication to delivering high-quality, effective, and affordable medical products.